A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications
Mett et al. describe development of GP532, a substantially deimmunized derivative of Toll-like receptor 5 (TLR5) agonist entolimod. GP532 has mutations eliminating key B- and T-cell epitopes and an inflammasome-activating domain yet remains a potent NF-κB activator with biological effects similar to...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/bcafc6dab7b74c02bc2aec45e9ac993a |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|